S. 3Senate110th Congress (2007-2009)Failed

Medicare Prescription Drug Price Negotiation Act of 2007

Sponsored by Harry ReidSen. Harry Reid (D-NV)
Introduced January 4, 2007

Legislative Activity

Stay on top of the latest movement without scrolling through every action

11 earlier actions
SenateFloor Latest Action

Motion by Senator Reid to reconsider the vote by which cloture on the motion to proceed was not invoked [Record Vote Number 132] entered in Senate.

April 18, 2007

View full timeline
SenateIntro Referral

Introduced in Senate

January 4, 2007

SenateIntro Referral

Sponsor introductory remarks on measure. (CR S9-11)

January 4, 2007

SenateIntro Referral

Read twice and referred to the Committee on Finance. (text of measure as introduced: CR S48)

January 4, 2007

SenateCommittee

Committee on Finance. Ordered to be reported with an amendment in the nature of a substitute favorably.

April 12, 2007

SenateCommittee

Committee on Finance. Reported by Senator Baucus under authority of the order of the Senate of 04/12/2007 with an amendment in the nature of a substitute. Without written report.

April 13, 2007

SenateCalendars

Placed on Senate Legislative Calendar under General Orders. Calendar No. 118.

April 13, 2007

SenateFloor

Motion to proceed to consideration of measure made in Senate. (consideration: CR S4461)

April 16, 2007

SenateFloor

Cloture motion on the motion to proceed presented in Senate. (consideration: CR S4461; text: CR S4461)

April 16, 2007

SenateFloor

Motion to proceed to consideration of measure withdrawn in Senate. (consideration: CR S4461)

April 16, 2007

SenateFloor

Motion to proceed to measure considered in Senate. (consideration: CR S4634-4636)

April 18, 2007

SenateFloor

Cloture on the motion to proceed to the bill not invoked in Senate by Yea-Nay Vote. 55 - 42. Record Vote Number: 132. (consideration: CR S4634; text: CR S4634)

April 18, 2007

SenateFloor

Motion by Senator Reid to reconsider the vote by which cloture on the motion to proceed was not invoked [Record Vote Number 132] entered in Senate.

April 18, 2007

Floor Debate

22 members

What members said about S. 3 on the floor

8 Republicans14 Democrats
Daniel K. Inouye
Sen. Daniel K. InouyeD-HI · Jan 4, 2007

Mr. President, I rise today to introduce the Rural Preventive Health Care Training Act, a bill that responds to the dire need of our rural communities for quality health care and disease prevention…

John F. Kerry
Sen. John F. KerryD-MA · Jan 4, 2007

Mr. President, today the first bill I am introducing in the 110th Congress is the Kids Come First Act, legislation that would ensure every child in America has health care coverage. The Kids Come…

John McCain
Sen. John McCainR-AZ · Jan 4, 2007

Mr. President, I am pleased to be joined today by Senators Snowe, Biden, and Lieberman in introducing the Rail Security Act of 2007. This legislation is nearly identical to the rail security measures…

Max Baucus
Sen. Max BaucusD-MT · Jan 4, 2007

Mr. President, back in 1962, Marshall McLuhan wrote, ``The new electronic interdependence recreates the world in the image of a global village.'' Certainly, 40 years later, that concept is truer than…

Chuck Grassley
Sen. Chuck GrassleyR-IA · Apr 17, 2007

Mr. President, I ask unanimous consent that the order for the quorum call be rescinded. Mr. President, I ask to speak as in morning business for half an hour, although I probably will not speak that…

Show 8 more
Harry Reid
Sen. Harry ReidD-NV · Jan 4, 2007

Mr. President, I appreciate everyone's courtesy. This is the first experience of mine to go through these procedures. It wasn't as smooth as clockwork, but with staff help it was smooth enough. So I…

Dianne Feinstein
Sen. Dianne FeinsteinD-CA · Jan 4, 2007

Mr. President, I rise today to introduce legislation that will bring to a close 18 years of litigation between the Natural Resources Defense Council, the Friant Water Users Authority and the U.S.…

Wayne Allard
Sen. Wayne AllardR-CO · Jan 4, 2007

Mr. President, another piece of legislation that I am introducing today addresses an issue important to citizens of southern Colorado. The problem is this: cable and satellite subscribers in two…

Patrick J. Leahy
Sen. Patrick J. LeahyD-VT · Jan 4, 2007

Mr. President, I am pleased to join with Senator Pryor to introduce the ``Effective Corruption Prosecutions Act of 2007,'' a bill to strengthen the tools available to Federal prosecutors in combating…

Barbara Boxer
Sen. Barbara BoxerD-CA · Jan 4, 2007

Mr. President, I am introducing a bill that would require that tap water be tested for perchlorate, and would ensure the public's right to know about perchlorate in their drinking water. I am pleased…

James M. Inhofe
Sen. James M. InhofeR-OK · Jan 4, 2007

Mr. President, I rise today, as an experienced pilot over age 60, along with my colleagues, Senator Stevens, Senator Lieberman and Senator Feingold, to once again introduce a bill that will help end…

Susan M. Collins
Sen. Susan M. CollinsR-ME · Jan 4, 2007

Mr. President, I rise today to join my colleagues in cosponsoring S. 1, a bill to provide greater transparency in the legislative process. The recent elections sent a clear message to Congress that…

John F. Kerry
Sen. John F. KerryD-MA · Apr 17, 2007

Mr. President, I ask unanimous consent I be permitted to proceed as in morning business for such time as I may consume. I thank the Chair. Mr. President, let me just comment. I did not come to the…

Show 11 more
Ken Salazar
Sen. Ken SalazarD-CO · Mar 26, 2007

Mr. President, I come to the Senate floor to speak about the issue of energy and the importance of this Senate and this Congress and this country moving forward with an authentic picture with respect…

Herb Kohl
Sen. Herb KohlD-WI · Jan 4, 2007

Mr. President, I rise today on the first day of this new Congress to introduce the Citizen Petition Fairness and Accuracy Act of 2007. This legislation will help speed the introduction of cost-saving…

Barack Obama
Sen. Barack ObamaD-IL · Jan 4, 2007

Mr. President, I rise today to introduce legislation that is significant both in the problems it seeks to address and the man it seeks to honor. Since the day he arrived in Congress more than two…

Harry Reid
Sen. Harry ReidD-NV · Apr 10, 2007

Madam President, throughout the world, Easter has been celebrated. This was done on Sunday. On that joyous day, Pope Benedict spoke of the human condition with a very heavy heart, and I quote: How…

Mary L. Landrieu
Sen. Mary L. LandrieuD-LA · Jan 4, 2007

Mr. President, at the end of the 109th Congress, I learned that the Internal Revenue Service had a tax surprise for citizens in my state of Louisiana and in Mississippi who are trying to rebuild…

Arlen Specter
Sen. Arlen SpecterR-PA · Jan 4, 2007

Mr. President, I will introduce legislation denominated the Habeas Corpus Restoration Act. Last year, in the Military Commissions Act, the constitutional right of habeas corpus was attempted to be…

Daniel K. Akaka
Sen. Daniel K. AkakaD-HI · Jan 4, 2007

Mr. President, I rise to introduce ``The Intelligence Community Audit Act of 2007,'' with Senator Lautenberg. This legislation reaffirms the authority of the Comptroller General of the United States…

Edward M. Kennedy
Sen. Edward M. KennedyD-MA · Jan 4, 2007

Mr. President, few things are more indispensable to the United States than good schools. Today more than ever, a quality education is the gateway to achieving the American dream and the best…

Olympia J. Snowe
Sen. Olympia J. SnoweR-ME · Jan 4, 2007

Mr. President, I rise today as a proud cosponsor of S. 3988, the Lane Evans Veterans Healthcare and Benefits Improvement Act of 2007. After serving with Lane Evans in the House of Representatives for…

Jim Bunning
Sen. Jim BunningR-KY · Jan 4, 2007

Mr. President, I rise today to introduce the Coal-to- Liquid Fuel Promotion Act of 2007. For too long, America has ignored its energy security. Many of us can remember the energy crises of the 1970s.…

Frank R. Lautenberg
Sen. Frank R. LautenbergD-NJ · Jan 4, 2007

Mr. President, I rise today with great pride to reintroduce legislation which would create a national park in my hometown of Paterson, NJ, The Paterson Great Falls National Park Act of 2007, which I…

Bill Text

2 versions available

Reading Mode
Latest
Reported to SenateIssued April 13, 2007

II

Calendar No. 118

110th CONGRESS

1st Session

S. 3

IN THE SENATE OF THE UNITED STATES

January 4, 2007

Mr. Reid (for himself, Mr. Baucus, Mr. Leahy, Ms. Mikulski, Mr. Schumer, Mrs. Clinton, Ms. Cantwell, Mr. Kohl, Ms. Stabenow, Mr. Webb, Mrs. Boxer, Mr. Brown, Ms. Klobuchar, Mr. Casey, and Mr. Levin) introduced the following bill; which was read twice and referred to the Committee on Finance

April 13, 2007

Reported under authority of the order of the Senate of April 12, 2007, by Mr. Baucus, with an amendment

Strike out all after the enacting clause and insert the part printed in italic

A BILL

To amend part D of title XVIII of the Social Security Act to provide for fair prescription drug prices for Medicare beneficiaries.

1.

Short title; sense of the Congress

(a)

Short title

This Act may be cited as the Medicare Prescription Drug Price Negotiation Act of 2007.

(b)

Sense of the Congress

It is the sense of the Congress that the Congress should enact, and the President should sign, legislation to amend part D of title XVIII of the Social Security Act to provide for fair prescription drug prices for Medicare beneficiaries.

1.

Short title

This Act may be cited as the Medicare Fair Prescription Drug Price Act of 2007.

2.

Repeal of prohibition

(a)

Repeal of prohibition

(1)

In general

Section 1860D–11(i) of the Social Security Act (42 U.S.C. 1395w–111(i)) is amended by striking the Secretary— and all that follows through may not require and inserting the Secretary may not require.

(2)

Rule of construction

Nothing in the amendment made by paragraph (1) shall be construed as doing any of the following:

(A)

Preventing the sponsor of a prescription drug plan or an MA organization offering an MA–PD plan under part D of title XVIII of the Social Security Act from obtaining a discount or reduction of the price for a covered part D drug.

(B)

Affecting the authority of the Secretary of Health and Human Services to ensure appropriate and adequate access to covered part D drugs under prescription drug plans and under MA–PD plans under such part, including compliance of such plans with formulary requirements under section 1860D–4(b)(3) of the Social Security Act (42 U.S.C. 1395w–104(b)(3)).

(C)

Limiting access by individuals enrolled in such prescription drug plans and MA–PD plans to community pharmacies.

(3)

Conduct of negotiations

Section 1860D–11 of the Social Security Act (42 U.S.C. 1395w–111) is amended by adding at the end the following new subsection:

(k)

Efforts to promote and ensure access to fair prices

(1)

Use of agency resources

To the extent that the Secretary promotes and ensures access to fair prices by engaging in any direct negotiations with a drug manufacturer with respect to prices for covered part D drugs, the Secretary—

(A)

may only do so utilizing the resources of the Department of Health and Human Services; and

(B)

may not enter into a contract with any public or private entity or enter into an Interdepartmental Agreement for the purpose of conducting such negotiations.

.

(b)

Accountability

Section 1860D–11(k) of the Social Security Act, as added by subsection (a)(3), is amended by adding at the end the following new paragraph:

(2)

Annual report on efforts to promote and ensure access to fair prices

The Secretary shall submit to Congress an annual report on the efforts of the Secretary to promote and ensure access to fair prices for prescription drugs under this part.

.

(c)

Effective date

The amendments made by this section shall take effect on the date of enactment of this Act.

3.

Greater transparency of part D prices and information

(a)

Access of congressional support agencies to data on prescription drug plans and Medicare Advantage plans

Section 1860D–42 of the Social Security Act (42 U.S.C. 1395w–152) is amended by adding at the end the following new subsection:

(c)

Providing part D data to congressional support agencies

(1)

In general

Notwithstanding any provision under this part that limits the use of prescription drug data collected under this part and subject to the restriction under paragraph (6), upon the request of a congressional support agency, the Secretary shall provide such agency with the following data collected from, or related to, prescription drug plans and MA–PD plans:

(A)

Aggregate negotiated price concessions

Aggregate negotiated price concessions described in section 1860D–2(d)(2) (as determined necessary and appropriate by the congressional support agency to carry out the legislatively mandated duties of the agency).

(B)

Negotiated price concessions

The negotiated rebates, discounts, and other price concessions (as currently reported pursuant to section 1860D–2(d)(2)).

(C)

Drug claims data

Data or a representative sample of data regarding drug claims submitted under section 1860D–15(c)(1)(C) (as determined necessary and appropriate by the congressional support agency to carry out the legislatively mandated duties of the agency).

(D)

Reinsurance payments

The amount of reinsurance payments paid under section 1860D–15(a)(2), provided at the plan level.

(E)

Risk-corridor payments

The amount of any adjustments of payments made under subparagraph (B) or (C) of section 1860D–15(e)(2), provided at the plan level.

(2)

Prohibition on disclosure of data by congressional support agencies

(A)

Data provided to a congressional support agency under this subsection shall not—

(i)

be disclosed by such agency in the performance of the agency’s duties in cases where such disclosure by the Secretary would be prohibited under applicable Federal law, or where such disclosure would result in the disclosure of trade secrets; and

(ii)

be disclosed, reported, or released by such agency in identifiable form.

(B)

Identifiable form

For purposes of subparagraph (A)(ii), the term identifiable form means any representation of information described in subparagraphs (A) through (E) of paragraph (1) that permits identification of a specific prescription drug plan, MA–PD plan, pharmacy benefit manager, drug manufacturer, drug wholesaler, drug, or individual enrolled in a prescription drug plan or an MA–PD plan under this part.

(3)

Safeguarding data

Each congressional support agency shall adopt and maintain reasonable safeguards to protect against the unauthorized disclosure of data provided under this subsection. Such safeguards shall only permit the congressional support agency to disclose the data to another agency or entity if the agency or entity is—

(A)

under a subcontract with the congressional support agency to support any analysis conducted by the congressional support agency with respect to such data; and

(B)

is subject to the same data disclosure provisions and safeguards as the congressional support agency is subject to under this paragraph and paragraph (2).

(4)

Disclosure exemption

Data provided under this subsection shall be exempt from disclosure under section 552 of title 5, United States Code.

(5)

Congressional support agency defined

In this subsection, the term congressional support agency means—

(A)

the Medicare Payment Advisory Commission;

(B)

the Congressional Research Service;

(C)

the Congressional Budget Office; and

(D)

the Government Accountability Office.

(6)

Restriction on disclosure of price concessions

The Secretary may only release data on the negotiated price concessions described in paragraph (1)(B) to the congressional support agency described in paragraph (5)(C).

(7)

Rule of construction

Nothing in this subsection shall be construed to limit the ability of a congressional support agency to obtain information not described in paragraph (1).

.

(b)

Study on market competition and reports on limitations of data elements for studying the prescription drug program

(1)

Study and report on market competition by the Congressional Budget Office

(A)

In general

The Director of the Congressional Budget Office shall conduct a study on the effect of market competition on prices for drugs under part D of title XVIII of the Social Security Act (42 U.S.C. 1395w–101 et seq.) that includes a review of—

(i)

the number and extent of discounts and other price concessions received by prescription drug plans and MA–PD plans for covered part D drugs under such part;

(ii)

the relationship between such discounts and price concessions and drug utilization;

(iii)

the relationship between such discounts and price concessions and the manufacturer’s best price (as defined in section 1927(c)(2)(B) of the Social Security Act (42 U.S.C. 1396r–8(c)(2)(B)) for covered outpatient drugs; and

(iv)

the extent to which the efforts of the Secretary of Health and Human Services (as reported by the Secretary under section 1860D–11(k) of the Social Security Act, as added by section 2(b)) to promote and ensure access to fair prices for prescription drugs under such part have an effect upon payers in non-Medicare markets.

(B)

Report

Not later than 1 year after the date of enactment of this Act, the Director of the Congressional Budget Office shall submit a report containing the results of the study conducted under subparagraph (A).

(2)

Reports on limitations of data elements for studying the prescription drug program

Not later than 180 days after the date of enactment of this Act, the Medicare Payment Advisory Commission and the Government Accountability Office shall each submit a report to Congress commenting on the limitations on the usefulness of the data described in subparagraphs (A) through (E) of section 1860D–42(c)(1), as added by subsection (a), to inform Congress on negotiated prices for covered part D drugs (as defined in section 1860D–2(e) of such Act (42 U.S.C. 1395w–102(e)) under the Medicare prescription drug program.

(c)

Disclosure of drug claims data to the State agency responsible for administering the state plan under the medicaid program

Section 1860D–42 of the Social Security Act (42 U.S.C. 1395w–152), as amended by subsection (a), is amended by adding at the end the following new subsection:

(d)

Disclosure of drug claims data to the State agency responsible for administering the state plan under the medicaid program

Notwithstanding any provision under this part that limits the use of prescription drug data collected under this part, upon the request of a State agency with responsibility for administering the State plan under title XIX, the Secretary shall provide such State agency with the data described in paragraph (1)(C) of subsection (c) with respect to full-benefit dual eligible individuals (as defined in section 1935(c)(6)) who are enrolled in the State plan. The provisions of paragraphs (2) and (3) of subsection (c) shall apply to a State agency with respect to data provided under this subsection in the same manner as such provisions apply to a congressional support agency with respect to data provided under subsection (c).

.

(d)

Public disclosure of data by the Secretary of Health and Human Services

Section 1860D–42 of the Social Security Act (42 U.S.C. 1395w–152), as amended by subsections (a) and (c), is amended by adding at the end the following new subsection:

(e)

Disclosure of drug prices charged to enrollees

(1)

In general

The Secretary shall make available to the public, upon request and in an electronic form determined appropriate by the Secretary, data on the prices charged for each covered part D drug under each prescription drug plan and MA–PD plan to individuals enrolled in the plan. Such data shall reflect actual prices posted on the Internet website of the Centers for Medicare & Medicaid Services and shall be made available in a manner that permits linkage of the data to data contained in other public prescription drug plan and MA–PD plan data files.

(2)

Nominal fee for data provided

The Secretary may charge a nominal fee for data provided under paragraph (1) based on the cost of preparing and providing such data.

.

(e)

Dissemination of retail drug prices

Section 1860D–4(k) of the Social Security Act (42 U.S.C. 1395w–104(k)) is amended—

(1)

in the heading, by striking pharmaceutical prices for equivalent drugs and inserting prescription drug information at point of sale;

(2)

by striking In general.—A PDP sponsor and inserting “Pharmaceutical prices for equivalent drugs.—

(A)

In general

A PDP sponsor

;

(3)

by redesignating paragraph (2) as subparagraph (B) and indenting appropriately;

(4)

by redesignating subparagraphs (A) and (B) as clauses (i) and (ii), respectively, and indenting appropriately;

(5)

in clause (i), as redesignated under paragraph (4)—

(A)

by striking subparagraph (B) and inserting clause (ii); and

(B)

by striking paragraph (1) and inserting subparagraph (A); and

(6)

by adding at the end the following new paragraph:

(2)

Drug prices charged to enrollees

(A)

In general

A PDP sponsor offering a prescription drug plan shall provide that each pharmacy that dispenses a covered part D drug shall inform an enrollee of the price charged for such drug under the prescription drug plan.

(B)

Timing of notice

The information under subparagraph (A) shall be provided at the time of purchase of the drug involved, including for purchases of covered part D drugs by mail order.

.

4.

Prioritizing studies of comparative clinical effectiveness of covered part D drugs

(a)

Priorities

(1)

In general

The Secretary of Health and Human Services (in this section referred to as the Secretary) shall develop a comprehensive prioritized list of comparative clinical effectiveness studies that are most critical to building the evidence needed to advance value-based purchasing of covered part D drugs (as defined in section 1860D–2(e) of the Social Security Act (42 U.S.C. 1395w–102(e)) under the Medicare prescription drug program under part D of title XVIII of such Act.

(2)

Requirements

(A)

Development of list

In developing the list under paragraph (1), the Secretary shall take into account—

(i)

the work the Agency for Healthcare Research and Quality has already done to identify needed comparative clinical effectiveness and safety research on prescription drugs, including the work identifying issues for which existing scientific evidence is insufficient under subsection (a)(3)(A)(ii) of section 1013 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (42 U.S.C. 299b–7);

(ii)

the initial list of medical conditions considered a priority for research that was developed in response to the requirements of subsection (a)(2)(B) of such section 1013;

(iii)

areas where patients and doctors are most lacking the information needed to make the best decisions regarding covered part D drugs, such as the areas where there is a large gap in knowledge of drug therapies and areas that involve the most widely prescribed covered part D drugs; and

(iv)

any advice provided by the advisory committee established under paragraph (3).

(B)

Contents of prioritized list

(i)

Specification of items, services, and methodology

The prioritized list shall specify the items and services to be evaluated, as well as the general methodology that should be used to conduct each study identified as a priority on the list, taking into consideration the full range of methodologies available, from systematic reviews to clinical trials.

(ii)

Studies included

The studies included on the prioritized list may include studies that compare a covered part D drug to any other drug (or biological product), item, or service that is covered under the Medicare program.

(C)

Report to Congress

(i)

In general

Not later than 1 year after the date of enactment of this Act and subject to the requirements under clause (ii), the Secretary shall submit to Congress a report that contains the following:

(I)

The prioritized list developed under paragraph (1) and plans for the conduct of studies identified as a priority on such list.

(II)

A summary of the information described in clauses (i) through (iv) of subparagraph (A).

(III)

An explanation of how the Secretary took into account the information described in such clauses (i) through (iv) in developing the prioritized list and in preparing the report.

(IV)

The rationale for why the Secretary included the studies identified as a priority on such list.

(ii)

Submission of draft report

Before submitting the report under clause (i), the Secretary shall—

(I)

submit to Congress a draft version of the report;

(II)

make such draft version available to the public; and

(III)

provide a 60-day period for public comment on such draft version.

(D)

Availability of report

The Secretary shall make the report submitted under subparagraph (C)(i) available to the public.

(3)

Establishment of advisory committee

(A)

Establishment

The Secretary shall establish an advisory committee for the purpose of providing advice to the Secretary on setting priorities for comparative clinical effectiveness studies across all agencies of the Department of Health and Human Services. The Secretary shall make available to the public any advice provided to the Secretary by the advisory committee.

(B)

Membership

(i)

In general

The advisory committee shall include a diverse range of public and private clinical experts, stakeholders, and interests from the following groups:

(I)

The medical and health industries.

(II)

Patients and representatives of patients.

(III)

Researchers.

(IV)

Government.

(ii)

No majority of membership from any one group

The Secretary shall ensure that the advisory committee does not have a majority of members from any one of the groups described in subclauses (I) through (IV) of clause (i).

(C)

Public comment

The Advisory committee shall provide a substantial opportunity for public comment by accepting oral and written comments from the public prior to making any recommendations or providing any advice to the Secretary.

(b)

Rule of construction

Nothing in this section shall be construed to limit the authority of the Secretary—

(1)

to prioritize comparative clinical effectiveness research needs for procedures, devices, diagnostics, or other medical interventions; or

(2)

to conduct any study on the list developed under subsection (a)(1) or any other study determined appropriate by the Secretary.

(c)

Authorization of appropriations

There are authorized to be appropriated such sums as may be necessary to carry out this section.

5.

Authorizing consideration of comparative clinical effectiveness studies in developing and reviewing formularies under the medicare prescription drug program

(a)

In general

Section 1860D–4(b)(3)(B) of the Social Security Act (42 U.S.C. 1395w–104(b)(3)(B)) is amended—

(1)

in clause (i), by striking and at the end;

(2)

in clause (ii), by striking the period at the end and inserting ; and; and

(3)

by adding at the end the following new clause:

(iii)

take into account relevant comparative clinical effectiveness studies.

.

(b)

Effective date

The amendments made by subsection (a) shall apply to plan years beginning on or after January 1, 2007.

6.

Sense of the senate regarding the resource standard used to determine eligibility for premium and cost-sharing subsidies under part D

(a)

Findings

The Senate makes the following findings:

(1)

Currently, beneficiaries enrolled in the Medicare part D prescription drug program must satisfy a resource standard in order to be eligible for the low-income subsidy.

(2)

The resource standard used to determine eligibility for the low-income subsidy has resulted in many Medicare beneficiaries who are in financial need being disqualified from receiving additional assistance.

(3)

Under S. 1 from the 108th Congress, as passed by the Senate, beneficiaries were not subjected to a resource standard to qualify for additional assistance.

(b)

Sense of the senate

It is the Sense of the Senate that Congress should revisit the resource standard used to determine the eligibility of individuals for premium and cost-sharing subsidies under section 1860D–14 of the Social Security Act (42 U.S.C. 1395w–114).

7.

Sense of the senate regarding pharmacy issues under part D

(a)

Findings

(1)

Pharmacists play a critical role in delivering prescription drugs to Medicare beneficiaries enrolled in prescription drug plans and MA–PD plans under the Medicare part D prescription drug program.

(2)

Pharmacists have encountered difficulties in providing services under their contracts with PDP sponsors offering prescription drug plans and MA organizations offering MA–PD plans under part D.

(b)

Sense of the senate

It is the sense of the Senate that Congress should address issues related to pharmacies under the Medicare part D prescription drug program.

April 13, 2007

Reported with an amendment